These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21541617)

  • 21. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling.
    Kanashiro CA; Schally AV; Zarandi M; Hammann BD; Varga JL
    Int J Cancer; 2004 Nov; 112(4):570-6. PubMed ID: 15382037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonists of growth hormone-releasing hormone in oncology.
    Schally AV; Varga JL
    Comb Chem High Throughput Screen; 2006 Mar; 9(3):163-70. PubMed ID: 16533148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro.
    Csernus VJ; Schally AV; Kiaris H; Armatis P
    Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3098-103. PubMed ID: 10077643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents.
    Schally AV; Varga JL
    Trends Endocrinol Metab; 1999 Dec; 10(10):383-391. PubMed ID: 10542394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
    Zarandi M; Varga JL; Schally AV; Horvath JE; Toller GL; Kovacs M; Letsch M; Groot K; Armatis P; Halmos G
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4610-5. PubMed ID: 16537407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
    Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone.
    Kiaris H; Schally AV
    Proc Natl Acad Sci U S A; 1999 Jan; 96(1):226-31. PubMed ID: 9874800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.
    Zarandi M; Horvath JE; Halmos G; Pinski J; Nagy A; Groot K; Rekasi Z; Schally AV
    Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12298-302. PubMed ID: 7991622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.
    Kanashiro CA; Schally AV; Zarandi M; Hammann BD; Varga JL
    Int J Oncol; 2007 Apr; 30(4):1019-28. PubMed ID: 17332943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors.
    Reeve JG; Morgan J; Schwander J; Bleehen NM
    Cancer Res; 1993 Oct; 53(19):4680-5. PubMed ID: 7691401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
    Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the growth hormone-releasing hormone (GH-RH) antagonist on brain functions in mice.
    Telegdy G; Tanaka M; Schally AV
    Behav Brain Res; 2011 Oct; 224(1):155-8. PubMed ID: 21672558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.
    Schally AV; Varga JL; Engel JB
    Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):33-43. PubMed ID: 18084344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of long-acting antagonists of growth hormone (GH)-releasing hormone on GH and cyclic adenosine 3',5'-monophosphate release in superfused rat pituitary cells.
    Horváth JE; Zarándi M; Groot K; Schally AV
    Endocrinology; 1995 Sep; 136(9):3849-55. PubMed ID: 7649091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
    Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth.
    Szepeshazi K; Schally AV; Armatis P; Groot K; Hebert F; Feil A; Varga JL; Halmos G
    Endocrinology; 2001 Oct; 142(10):4371-8. PubMed ID: 11564700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of proliferation, VEGF secretion of human neuroendocrine tumor cell line NCI-H727 by an antagonist of growth hormone-releasing hormone (GH-RH) in vitro.
    Sacewicz M; Lawnicka H; Siejka A; Stepień T; Krupiński R; Komorowski J; Stepień H
    Cancer Lett; 2008 Sep; 268(1):120-8. PubMed ID: 18486324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of neurotransmitters in the action of growth hormone-releasing hormone antagonist on passive avoidance learning.
    Telegdy G; Schally AV
    Behav Brain Res; 2012 Aug; 233(2):326-30. PubMed ID: 22640814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.